Peter Sikiric, the peptide's principal investigator, has stated: "BPC-157 has demonstrated a remarkable safety profile across hundreds of experimental applications, with no observed lethal dose in any tested species and consistent organ-protective effects rather than organ-damaging ones" 1
MHB containing GSH at concentrations of 0, 5, 10, 15, 20, 25, and 30 mM exhibited pH levels of 7.1, 5.9, 5.2, 4.4, 4.1, 4.0, and 4.0, respectively
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase
This safety profile combined with broad effectiveness explains the growing interest among both researchers and those seeking alternatives to conventional treatments
(Frontiers in Pharmacology, 2022) reports a half-life under 30 minutes after IM or IV administration in rodent and dog models, which is why split-dose schedules appear in the literature